ACG临床指南:胃癌前病变的诊断与管理
美国胃肠病学会发布首版胃癌前病变指南,涵盖高危患者内镜监测、高质量内镜与图像增强内镜诊断、组织学标准与报告、异型增生内镜治疗、幽门螺杆菌根除及自身免疫性胃炎和胃上皮息肉管理;推荐高危个体每3年监测,所有患者检测并根除幽门螺杆菌。
要点
- 推荐根据内镜、组织学及人口学因素界定的高危个体接受监测内镜,通常每3年一次,可个体化调整间隔。
- 推荐所有胃癌前病变患者进行幽门螺杆菌检测、治疗并确认根除。
- 美国人群胃腺癌/胃癌前病变内镜筛查证据不足,无法给出推荐。
核心结论
- 推荐对由内镜、组织学和人口学因素定义的高危胃癌前病变进展个体进行监测内镜,通常每3年一次,但可个体化调整间隔。
- 推荐所有胃癌前病变个体进行幽门螺杆菌检测、治疗和根除确认。
- 美国人群中胃腺癌/胃癌前病变内镜筛查证据不足,无法给出推荐。
研究设计与样本
- 美国胃肠病学会(ACG)首版胃癌前病变临床指南。
主要发现
- 美国胃腺癌发病率在非白人个体中高2至13倍,尤其是来自高发地区的早期移民。
- 美国胃腺癌5年生存率为36%,低于全球标准,因仅小部分病例在早期可治愈阶段诊断。
- 缺乏美国人群胃癌前病变管理的高质量数据,但证据持续积累。
关键数值与推荐
- 推荐高危胃癌前病变进展个体接受监测内镜,通常每3年一次,可个体化调整间隔。
- 推荐所有胃癌前病变个体进行幽门螺杆菌检测、治疗和根除确认。
- 美国高危人群胃腺癌/胃癌前病变上消化道内镜筛查证据不足,无法给出推荐。
临床怎么用
- 对高危胃癌前病变进展个体按推荐间隔进行监测内镜。
- 对所有胃癌前病变个体检测并根除幽门螺杆菌,并确认根除。
局限性
- 缺乏美国人群胃癌前病变管理的高质量数据。
- 美国高危人群胃腺癌/胃癌前病变内镜筛查证据不足,无法给出推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastric premalignant conditions (GPMC) are common and include atrophic gastritis, gastric intestinal metaplasia, dysplasia, and certain gastric epithelial polyps. GPMC have an increased risk of progression to gastric adenocarcinoma. Gastric cancer (GC) in the United States represents an important cancer disparity because incidence rates are 2- to 13-fold greater in non-White individuals, particularly early-generation immigrants from regions of high GC incidence. The US 5-year survival rate for GC is 36%, which falls short of global standards and is driven by the fact that only a small percentage of GC in the US is diagnosed in the early, curable stage. This document represents the first iteration of American College of Gastroenterology guidelines on this topic and encompasses endoscopic surveillance for high-risk patients with GPMC, the performance of high-quality endoscopy and image-enhanced endoscopy for diagnosis and surveillance, GPMC histology criteria and reporting, endoscopic treatment of dysplasia, the role of Helicobacter pylori eradication, general risk reduction measures, and the management of autoimmune gastritis and gastric epithelial polyps. There is insufficient evidence to make a recommendation on upper endoscopic screening for GC/GPMC detection in US populations deemed high-risk for GC. Surveillance endoscopy is recommended for individuals at high risk for GPMC progression, as defined by endoscopic, histologic, and demographic factors, typically every 3 years, but an individualized interval may be warranted. H. pylori testing, treatment, and eradication confirmation are recommended in all individuals with GPMC. Extensive high-quality data from US populations regarding GPMC management are lacking, but continue to accrue, and the quality of evidence for the recommendations presented herein should be interpreted with this dynamic context in mind. The GPMC research and education agendas are broad and include high-quality prospective studies evaluating opportunistic endoscopic screening for GC/GPMC, refined delineation of what constitutes "high-risk" populations, development of novel biomarkers, alignment of best practices, implementation of training programs for improved GPMC/GC detection, and evaluation of the impact of these interventions on GC incidence and mortality in the US.
引用
- Morgan DR, Corral JE, Li D, et al. ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions. Am J Gastroenterol. 2025. PMID: 40072510. doi:10.14309/ajg.0000000000003350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。